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The covalent attachment of polyethylene glycol (PEG) to therapeutical proteins is an important route to 
develop biobetters for biomedical, biotech and pharmaceutical industries. PEG conjugation can shield 
antigenic epitopes of the protein, reduce degradation by proteolytic enzymes, enhance long-term stability 
and maintain or even improve pharmacokinetic and pharmacodynamics characteristics of the protein 
drug. Nonetheless, correct information in terms of the PEGylation process from reaction to downstream 
processing is of paramount importance for the industrial application and processing scale-up. In this review 
we present and discuss the main steps in protein PEGylation, namely: PEGylation reaction, separation of 
the products and final characterization of structure and activity of the resulting species. These steps are 
not trivial tasks, reason why bioprocessing operations based on PEGylated proteins relies on the use of 
analytical tools according to the specific pharmaceutical conjugate that is being developed. Therefore, 
the appropriate selection of the technical and analytical methods may ensure success in implementing 
a feasible industrial process. 
Keywords: PEGylation. Biobetters. Biological drugs. Polyethylene glycol. Protein purification. Site-
specific PEGylation.
PEGYLATION FOR BIOBETTERS DEVELOP-
MENT AND PRODUCTION
Therapies based on biological drugs represented a 
revolutionary innovation in the pharmaceutical industry 
due to the success to overcome medical challenges, such 
as haemophilia, diabetes, arthritis and diseases of the 
immune system. Because of patent protection strategies 
and the high market price of biological drugs, the holding 
companies of innovative molecules generated considerable 
revenue (Calo-Fernández, Martínez-Hurtado, 2012). In 
2016, global market of biological drugs reached US$ 
209.8 billion (Transparency Market Research, 2016) 
and Roche® was the company with the highest income, 
reaching US $ 38.7 billion in 2015 (Spadiut et al., 2014). 
However, some drawbacks are intrinsically related to 
biological drugs, more specifically to protein drugs that 
usually present immunogenicity and short plasma half-life. 
The immunogenicity is mainly related to the production of 
anti-drug antibodies (ADA) that reduce clinical efficacy 
by biological activity neutralization or induction of 
hypersensitivity, which includes anaphylactic reactions 
(Barbosa et al., 2012; Kuriakose, Chirmule, Nair, 2016). 
The shorter biological half-life of protein drugs leads to 
more recurrent administrations to achieve the desired 
clinical effect in patients (Ryu, Kim, Nam, 2012). Another 
concern related to commercial protein drugs is of economic 
nature and is called “Patent Cliff”, a market phenomenon 
well described for chemical drugs that is happening with 
biological ones (Calo-Fernández, Martínez-Hurtado, 2012). 
It refers to a sharp drop in sales of blockbusters following the 
end of their patent protection, which can impact negatively 
or positively the main participants in the biological drug 
industry, depending on the marketing strategies adopted 
(Calo-Fernández, Martínez-Hurtado, 2012).
Considering the economic need to remain 
competitive in the market and the necessity to solve the 
inherent problems of biological drugs, a new generation 
of protein-based medicines emerge: the follow-on 
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biologics. This new generation of biological drugs is 
divided in two main groups: the biosimilars (Barbosa 
et al., 2012; Calo-Fernández, Martínez-Hurtado, 2012) 
and biobetters (Ryu, Kim, Nam, 2012; Gorham, 2015). 
Both biosimilars and biobetters are similar to a reference 
product; however, biosimilars aim to establish similarity 
to a known biological, whereas biobetters seek superiority 
in one or various aspects of their clinical profile (Sassi et 
al., 2015). In this sense, biosimilars have the same amino 
acid sequence of the originator biological drug, and must 
have also the same safety, purity and efficacy profile (Beck, 
Sanglier-Cianférani, Van Dorsselaer, 2012). On the other 
hand, a biobetter is a biological molecule that suffered 
chemical or molecular modifications from an originator 
to generate functional changes that include increased half-
life, reduced toxicity, reduced immunogenicity and/or 
enhanced pharmacodynamics (Beck, Sanglier-Cianférani, 
Van Dorsselaer, 2012; Sassi et al., 2015). 
Biobetters represent an opportunity for innovation 
with reduced risk and increased sales for manufacturers, 
since the mechanism of action of the originator molecule is 
already known. At the same time, they promote an improved 
treatment for patients and possibility of cost reduction for 
health systems. One of the main tools for the development 
of biobetters refers to PEGylation, a technique in which at 
least one chain of polyethylene glycol (PEG) is covalently 
attached to the structure of the protein (Figure 1) (Hoffman, 
2016). PEG is a biocompatible polymer, which presents 
minor immunogenicity, antigenicity and toxicity, is soluble 
in water and other organic solvents, is readily cleared 
from the body and has high mobility in solution, making 
this the polymer of choice for bioconjugation (Jevševar, 
Kunstelj, Porekar, 2010). Additionally, PEG is one of 
the few synthetic polymers approved by the US FDA for 
internal administration. After the first report of protein 
PEGylation in the 1970s (Hoffman, 2016), many proteins 
and peptides have been covalently conjugated with PEG 
and many more are currently under clinical trials. To date, 
14 biobetters (PEGylated proteins, peptides, antibody 
fragments, and oligonucleotides) have been approved by 
FDA and are currently on the market (Table I). From these, 
12 are PEGylated proteins, with a total market value of 
over US $ 8 billion per year (Ginn et al., 2014).
PEGylation technology was firstly reported in 1977 
(Abuchowski et al., 1977) for the modification of albumin 
and catalase. Depending on the number, molecular weight 
and location of the attached PEG chains, this covalent 
modification can enhance the physicochemical properties of 
the protein, without compromising the secondary structure 
(González-Valdez, Rito-Palomares, Benavides, 2012). 
The PEGylation strategy provides a number of advantages 
for protein conjugates, such as (i) protection of antigenic 
sites present on the protein surface, i.e. antigenic epitopes; 
(ii) prevention of in vivo degradation by endocytosis and 
proteolytic enzymes; (iii) increase in apparent protein size 
and hydrodynamic volume, which reduces renal filtration, 
alters biodistribution and increases in vivo half-life; 
(iv) increased water solubility and reduction of protein 
aggregates due to steric repulsion between the PEGylated 
surfaces; (v) increased thermal and long-term stability 
(Beck, Sanglier-Cianférani, Van Dorsselaer, 2012; Sassi, 
Nagarkar, Hamblin, 2015). It may also promote sustained 
release of originator drug (Monfardini et al., 1995; 
Veronese, Caliceti, Schiavon, 1997).
Several studies have focused on the use of protein 
PEGylation to develop novel biobetters. A thorough 
survey of the scientific literature from 1991 to November 
of 2017 yielded 1450 articles in which protein PEGylation 
was used in biobetter development (Figure 2). Therefore, 
it is undeniable that PEGylation is a hot-topic in the 
biopharmaceutical field. In this paper, we review the main 
concepts, strategies and pitfalls of protein PEGylation 
aiming at biobetter manufacturing.
PEGYLATION REACTION DESIGN 
Selecting the appropriate chemistry reaction in the 
design of PEGylated molecules is the first step in obtaining 
FIGURE 1 - (A) Chemical structure of  N-terminal reactive PEG and (B) schematic representation of a tetrameric protein PEGylated 
with 10,000 Da PEG chains at the N-terminal groups.
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a successful process (Pasut, Veronese, 2012; Pfister 
and Morbidelli 2014). PEGylation reactions have been 
extensively reviewed in literature (Jevševar, Kunstelj, 
Porekar, 2010; Palm, Esfandiary, Gandhi, 2011; Pasut, 
Veronese, 2012; Ginn et al., 2014; Pfister, Morbidelli, 
2014). The selection of the PEG derivative (the reactive 
PEG used in the PEGylation reaction) is fundamental, 
since it depends strongly on the location and number of 
amino-acids that are able to be PEGylated (Veronese, 
2001; Zhou, He, Wang, 2016). Generally, the reactive 
groups in proteins that covalently bind with activated PEG 
molecules are nucleophiles (Da Silva Freitas, Mero, Pasut, 
2013; Zhou, He, Wang, 2016), with the following moieties 
ranked in decreasing order of reactivity: thiol, α-amino, 
ɛ-amino, carboxyl, and hydroxyl (González-Valdez et al., 
2012). Moreover, the number and local reactivity of the 
available PEGylation sites (nucleophilic groups of the 
amino-acids), the experimental conditions of PEGylation 
reaction (i.e. pH, temperature, reaction time and molar 
ratio between PEG derivative and protein), and reactivity 
of the PEG derivative influence the final composition 
of PEGylated products (González-Valdez et al., 2012). 
PEG coupling may result in heterogeneous mixtures of 
PEGylated conjugates with several degrees of PEGylation 
and non-PEGylated forms (Pasut, Veronese, 2012).
PEGylation reactions are preferably conducted in 
a single-step unidirectional batch system to guarantee 
batch-to-batch control and the formation of all products in 
TABLE I - FDA-approved biotherapeutics PEGylated drugs in United and States and/or Europe
Brand name, generic name Company PEGylation site PEG size (Da) Indication(s)
Year of 
approval
Adagen®, pegademase bovine Enzon Lysines 5000
Severe combined 
immunodeficiency diseases 
(SCID)
1990
Oncaspar®, pegaspargase Enzon Lysines 5000 Acute lymphoblastic leukemia (ALL) 1994
PEG-INTRON®, 
PEGinterferon alpha 2b
Schering-
Plough
Histidine, cysteine, 
lysines, serine, 
tyrosine, histidine
12,000 Hepatitis C 2000
PEGASYS®, PEGinterferon 
alpha 2a
Hoffman-La 
Roche Lysines 40,000 Hepatitis C 2001
Neulasta®, pegfilgrastim Amgen N-terminal 20,000 Neutropenia 2002
Somavert®, pegvisomant Pfizer Lysines, N-terminal 5000 Acromegaly 2003
Macugen®, pegaptanib Pfizer Lysines 40,000 Age-related macular degeneration 2004
Mircera®, PEG-epoetin beta Hoffman-La Roche Lysines 30,000
Anemia associated with 
chronic renal failure 2007
Cimzia®, certolizumab pegol UCB C-terminal 40,000
Chronic, moderate to severe 
RA, Crohn’s disease, axial 
spondyloarthritis and psoriatic 
arthritis
2008
Krystexxa®, pegloticase Savient Lysines 10,000 Chronic gout 2010
SylatronTM, PEGinterferon1 
alpha 2b Merck
Histidine, cysteine, 
lysines, serine, 
tyrosine, histidine
12,000 Melanoma 2011
Omontys®, peginesatide Affymax/Takeda Lysines 40,000
Anemia associated with 
chronic kidney disease 2012
Plegridy®, peginterferon 
beta-1 Biogen N-terminal 20,000 Multiple sclerosis 2014
Adynovate®, pegylated 
antihemophilic factor Baxalta Lysines 20,000 Hemophilia A 2015
1 Sylatron™ is another brand name for peginterferon alfa-2b exclusively approved by FDA for adjuvant therapy in cancer treatment.
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equal conditions. In this sense, validation, reproducibility 
and optimization of the reaction are favoured, while 
enabling to easily trace the potential formation of 
undesirable products ( i .e.  PEGylation adducts) 
(González-Valdez et al., 2012). Also, maximization of 
the PEGylation yield and specificity of every reaction 
is required. The main challenges of PEGylation are (i) 
the design of site-specific PEGylation reactions to avoid 
heterogeneity of PEGylated conjugates; (ii) to obtain 
shortened-time reactions that increase PEGylation 
productivity; (iii) to decrease the amount of reactive PEG 
and the overall cost of the process.
Reactive PEGs for random PEGylation usually 
target amino groups of the protein, most frequently the 
ɛ-amino of the side-chains of lysine residues. Examples 
of randomly PEGylated biobetters available in the market 
are Adagen® and Oncaspar® (Table I), which are both 
complex mixtures of various PEGylated conjugates 
(higher polydispersity) at lysine residues and N-terminals. 
PEG-INTRON® (SylatronTM), PEGASYS®, Mircera® 
are also examples of randomly PEGylated drugs (Table 
I), but in this case they are mixtures of mono-PEGylated 
positional isomers exhibiting extended half-lifes in 
comparison to the originator drugs. PEGylation reactions 
can be directed towards the formation of site-specific 
PEGylated conjugates by the optimization of reaction 
conditions (Veronese, 2001; Zhao et al., 2012; Da Silva 
Freitas, Mero, Pasut, 2013). An example of a site-specific 
PEGylated biobetter available in the market is Neulasta® 
(Table I), an N-terminally mono-PEGylated granulocyte-
colony stimulating factor (G-CSF). 
PEGylation of therapeutic proteins usually involves 
the use of mono-methoxy PEG (mPEG), approved by FDA 
and EMA. Since it has only one reactive hydroxyl group, 
undesirable byproducts, i.e. crossed linked products, 
are avoided. (Jevševar, Kunstelj, Porekar, 2010; Sassi, 
Nagarkar, Hamblin, 2015) One of the most common 
mPEG is the amino reactive N-hydroxylsuccinimide 
(NHS) functionalized polyethylene glycol (PEG-NHS), 
used to modify proteins, peptides or any molecule/
structure with available amino groups. The reaction 
of NHS esters with primary amine groups at pH 7-8.5 
results in stable amide bonds. Compared to other PEG 
NHS ester derivatives, the succinimidyl carbonate (SC) 
functionalized mPEG-NHS offers superior reactivity and 
higher stability in aqueous solution (Nanocs, 2017). 
In PEGylation, linear PEGs are the conventional 
and simplest conjugate agents (Figure 3). With this type of 
PEGs, proteins are conjugated in the distal end of a PEG 
molecule in a single attachment site (Roberts, Bentley, 
Harris, 2012). Bifunctional PEGs are linear PEGs with 
two available sites for protein conjugation, meaning that 
in maximum only two biomolecules may be conjugated, 
which limits the loading capacity comparing to the most 
recent PEG derivatives (Veronese, Caliceti, Schiavon, 
1997; Gokarn, McLean, Laue, 2012). Nonetheless, 
bifunctional PEGs may significantly increase viscosity 
compared to the originator drug formulation since one 
reactive PEG molecule can conjugate to two different 
protein molecules, resulting in protein cross linking and 
a hydrogel formation. In addition, linear PEGs of large 
molecular weight may impede the appropriate release of 
small molecular weight protein drugs, preventing them to 
reach therapeutic concentrations at the target sites (when 
a cleavable PEG is employed) (Roberts, Bentley, Harris, 
2012). To overcome these drawbacks, several novel types 
FIGURE 2 - PubMed citations of the title words “Protein PEGylation” and “PEGylation” in published articles in the last 26 
years (from 1991 to 2017).
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of PEG derivatives have been synthesized, including 
Y-shaped PEGs, forked PEGs and multi-arm PEGs (Figure 
3) (Roberts, Bentley, Harris, 2012; Pfister, Morbidelli, 
2014). Y-shaped PEGs have an “umbrella like” structure, 
linking two linear PEG derivatives to active groups of 
amino acids. This structure provides better protection than 
linear PEGs toward antibodies recognition and cleavage 
by proteolytic enzymes. This PEG variant was tested in 
several proteins (i.e. ribonuclease, catalase, asparaginase, 
trypsin, among others), but is not applied as frequently 
for peptides and small molecules drugs (Monfardini et 
al., 1995). 
Forked PEGs provide multi-proximal reactive 
groups at one or both ends of a linear PEG chain 
(Veronese, Caliceti, Schiavon, 1997). The first report on a 
forked PEG synthesis dates from 1999 (Harris, Kozlowski, 
1999); it refers to the attachment to the terminus of 
the polymer backbone of a trifunctional linker, such as 
serinol or β-glutamic acid. Forked PEGs are useful for 
conjugating small molecules rather than proteins since 
conjugation of forked PEGs functionalized at both ends 
of the polymer chain generate protein hydrogels rather 
than soluble PEGylated proteins. Nonetheless, forked 
PEGs may find application in biobetters’ design attached 
to Fab’ antibody fragments to produce a conjugate similar 
in structure to the full-length antibody (Constantinou, 
Chen, Deonarain, 2010) Multi-arm PEGs are star-like 
structures carrying multi-hydroxyl or functional groups, 
increasing the amount of active sites and molecular weight 
(Kim et al., 2016). Similarly to fork-shaped PEGs, multi-
arm PEGs are not much explored in the attachment with 
proteins due to protein cross-link. They have been widely 
investigated for conjugation of small molecule drugs such 
as NKTR-102 (PEG-irinotecan) (Adkins et al., 2015), 
EZN-2208 (PEG-SN38) (Garrett et al., 2013) and NKTR-
214 (PEG- aldesleukin) (Charych et al., 2016), which are 
some examples of PEGylated drugs that have entered into 
clinical trials.
PEGylation processes may be classified in “first-
generation” and “second-generation”. First-generation 
processes involved random PEGylation, what results 
in multiple isoforms with a lack of control in the 
physicochemical and pharmaceutical properties of the 
final product (i.e. presence of mixtures of isomers with 
batch-to-batch variation and unstable bonds). Despite 
these limitations, first-generation PEGylated drugs 
are still in use today. Instead, the second-generation 
PEGylated biomolecules are obtained with novel PEG 
derivatives (Figure 3) including higher molecular weight 
and branched structures. In comparison to linear PEG, 
branched PEGylation decreases immunogenicity and 
increases half-life, but usually the decrease in activity of 
the biomolecules is more pronounced. Novel trends in 
PEGylation recognise a “third generation” technology, 
aiming to preserve the drug’s bioactivity, using novel 
non-linear PEG derivatives and alternative PEGylation 
strategies (Swierczewska, Lee, Lee, 2015) that will be 
further discussed below.
FIGURE 3 - Reactive PEGs used in PEGylation reactions. R represents functional groups of PEG derivatives. Linear - simplest 
and most often used conjugate agent with only one reactive group; Bifunctional – linear PEG derivative with two reactive groups; 
Y-shaped PEG - two linear PEG derivatives linked to a single point of attachment to proteins; Fork-shaped PEG - multi-proximal 
reactive groups at the end of one or both ends of a linear PEG chain; Multi-arm PEG – an eight-arm PEG carrying multi-hydroxyl 
or other functional groups (R) with pentaerythritol, hexaglycerol, or tripentaerythritol as the central core.
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Several sites of proteins can be targeted for 
PEGylation (Figure 4) and in the next subsections we 
will explore different PEGylation strategies that can be 
applied in the development of novel biobetters. 
PEGylation of ε-amino groups
Amine groups are present in large quantities on the 
surface of most therapeutic proteins as lysine residues or 
N-terminals and PEGylation of lysine ε-amino groups is 
the most studied type of PEGylation (Figure 5). It may be 
performed via the N-alkylation or N-acylation by using 
the activated PEG carbonates or carboxylates (Pasut, 
Veronese, 2012;,Zhang et al., 2012).
The main drawback of this approach is low 
selectivity of PEG position since after the random 
attachment to some lysine residues, steric hindrance may 
occur in neighbouring lysine residues. (Pfister, Morbidelli, 
2014) This leads to a significant variation in the number 
of chains introduced and their location, resulting in a 
mixture of heterogeneous isomers (Ginn et al., 2014) 
with batch-to-batch variation. The first two proteins to 
be PEGylated were adenosine deaminase (ADA) and 
asparaginase, with 5 kDa succinimidyl succinate-activated 
PEG (mPEG-SS): pegademase (Adagen®, 11-17 PEG 
molecules) and pegaspargase (Oncaspar®, 69-82 PEG 
molecules) (Turecek et al., 2016).
It is known that arginine residues are less prone 
to reaction with the reactive PEG due to delocalization 
of charge in the guanidinium group. Thus, molecular 
strategies such as replacement of lysine by arginine at 
essential sites often result in proteins with retention of 
activity and more controlled PEGylation at ε–amino 
groups. The reverse way, i.e. the replacement of some 
neutral residues by lysine at non-essential sites, add 
new regions for PEGylation. These strategies controls 
the number of possible PEGylation sites and may result 
in more homogeneous PEGylated preparations (Pasut, 
Veronese, 2012; Zhang et al., 2012).
PEGylation of thiols groups
Thiol groups are very suitable for site-specific 
PEGylation since specific covalent conjugation is possible 
even in the presence of other protein nucleophiles (Ginn 
et al., 2014) and the reduction of protein activity is 
usually lower. Few PEGylated thiol groups can already 
improve the pharmacokinetic properties of therapeutic 
FIGURE 4 - Potential sites of PEGylation in proteins. Typical reactive amino-acids including lysine, cysteine, glutamine, N-terminal 
amino group and the C-terminal carboxylic acid are specific sites for conjugation with PEG derivatives. 
FIGURE 5 - PEGylation of primary amines in proteins, forming an amide linkage.
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proteins (Zhang et al., 2012). The PEGylation agents most 
commonly used are maleimide PEGs such as orthopyridyl 
disulphide (PEG-OPSS) and tosylate (PEG-TS) to form 
a thioether bond by a Michael addition (Pasut, Veronese, 
2012; Pfister, Morbidelli, 2014). The reaction pH should 
be carefully buffered at values bellow lysine residues pKa 
(usually 9.3 to 10.5) to avoid the coupling of protein amine 
groups to maleimide (Pasut, Veronese, 2012).
The main limitation of this technique is that 
proteins rarely present cysteine residues in reduced form; 
they are generally involved in disulfide bonds. When 
present, reduced cysteine residues are located mainly in 
inaccessible hydrophobic domains and for that reason 
present low reactivity (Pasut, Veronese, 2012; Pfister, 
Morbidelli, 2014). This problem can be overcome using 
genetic engineering tools to insert one or more free 
cysteine residues on the protein surface to facilitate site-
specific PEGylation (Constantinou, Chen, Deonarain, 
2010). CIMZIA® is a PEGylated anti-TNF recombinant 
antibody Fab fragment, the only FDA approved protein 
with thiol group PEGylation (Figure 6). It is approved for 
treatment of rheumatoid arthritis, Crohn’s disease, and 
axial spondyloarthritis. CIMZIA® is produced in E. coli 
bacterium and covalently bound with 40-kDa branched 
PEG at a cysteine residue, which was inserted three amino 
acids from the C-terminus of the heavy chain antibody 
fragment by genetic engineering.(Turecek et al., 2016)
PEGylation of disulfide bond
Recently, the disulfide bonds were considered as 
targets for site-specific PEGylation, mainly as a way to 
overcome the lack of free cysteines in protein (Pfister, 
Morbidelli, 2014). Its applicability in therapeutic protein 
PEGylation is still under investigation, but it is known 
that disulfide bridges are present in small amounts in 
therapeutic proteins, making PEGylation at these sites 
attractive due to the possibility of obtaining homogeneous 
conjugates. However, the natural distance between the 
sulfur atoms must be preserved with PEGylation since 
these bonds are essential for protein conformation (Pasut, 
Veronese, 2012). The technique was first proposed by 
Brocchini et al. (Brocchini et al., 2006) using bis-thiol 
alkylating PEG reagent capable to form a three-carbon 
bridge after reducing the disulfide bonds of the protein. 
The mild reduction of the accessible native disufide bonds 
enable site-specific PEGylation in the sulfur atoms, while 
retaining the protein tertiary structure (Figure 7) (Pasut, 
Veronese, 2012; Kolate et al., 2014).
N-terminal and C-terminal PEGylation
N-terminal PEGylation is considered a site-directed 
reaction (Ginn et al., 2014), since there is only one group 
per protein chain and the number of PEGylation sites 
are dramatically reduced (Pfister, Morbidelli, 2014). 
The reaction selectivity is based on pKa differences 
between the ε-amino group of lysine residues (9.3-10.5) 
and the N-terminal α-amino group of proteins (7.6 to 
8). Accordingly, at pH values lower than 9.3 the lysine 
residues will be predominantly protonated and unavailable 
to react with active PEG (Pasut, Veronese, 2012). In some 
FIGURE 6 - Schematic conjugation of thiol PEGylation from antibody fragment with a PEG maleimide reagent (representing 
CIMZIA® conjugation).
FIGURE 7 - Schematic mechanism for a disulfide site-specific PEGylation.
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cases, the determination of the optimal pH conditions can 
be difficult since small changes may result in competition 
for other amine groups and optimum pH varies between 
proteins (Ginn et al. 2014). Molecular strategies can 
be used to improve selectivity, such as depletion or 
modification of some lysine residues on the protein surface 
(by chemical or genetic engineering) and functionalization 
of the N-terminal portion with reactive carbonyl groups 
that are more selective and efficient (Ginn et al., 2014; 
Pfister, Morbidelli, 2014). Neulasta® (Pegfilgrastim) and 
Plegridy® (Peginterferon β-1) are two examples of protein 
N-terminal PEGylation with 20 kDa PEG.
In the same way, each protein chain has one 
C-terminal portion that can be used for site-specific 
PEGylation. This reaction can be performed by introducing 
a hydrazine group at this location by fusion technique 
with inteins (Pasut, Veronese, 2012; Kolate et al., 
2014). An intein is a protein segment that is self-excised 
through a process known as protein splicing (Kolate et 
al., 2014). The conjugation reactions include the intein 
excision resulting in the protein of interest containing 
one hydrazine group at the C-terminal portion, which 
can react specifically with PEG molecules functionalized 
with aldehyde groups or ketone (Pasut, Veronese, 2012). 
This approach has been recently applied to IFN-α (Pasut, 
Veronese, 2012; Ginn et al., 2014; Kolate et al., 2014) 
and IFN-β (Thom et al., 2011), however, none PEGylated 
conjugate by this technique reached the stage of clinical 
research (Ginn et al., 2014).
Enzymatic PEGylation
This site-specific PEGylation is based on a 
transglutaminase (TGase) catalysed acyl transfer reaction 
between glutamine residues (Gln) and PEG primary 
amino groups in reactive PEGs (Figure 8) (Sato, 2002). 
For chimeric proteins, a short sequence of Gln residues is 
incorporated at the protein terminal by genetic engineering, 
without disturbing its flexibility and conformation, 
and then PEGylated with primary amine derivatives of 
PEGs in the presence of the enzyme. Compared with 
other strategies, TGase mediated conjugations were 
found to be more site-specific, reproducible and versatile 
(Fontana et al., 2008). Enzymatic PEGylations with TGase 
were already investigated for several proteins, such as 
apomyoglobin (apoMb), human growth hormone (hGH), 
α-lactalbumin (α-LA), human interlukin-2 (hIL-2) and 
human granulocyte colony-stimulating factor (hG-CSF) 
(Fontana et al., 2008; Mero et al., 2009). 
Released and non-covalent PEGylation
One of the main drawbacks of protein PEGylation 
is the activity loss of therapeutic proteins. One solution 
is to target amino acids in non-essential sites, but it is 
often necessary laborious protein engineering tools that 
can bring conformational changes in protein structure 
(Gong, Leroux, Gauthier, 2015). The reversible attachment 
of PEG polymer to the protein might be interesting to 
obtain conjugates with longer half-life while keeping 
pharmacodynamic properties (Pfister, Morbidelli, 2014). 
Some of the reactions for reversible PEGylation include 
bicine linker, histidine PEGylation, glucose and different 
ligands (“linkers”) that are cleaved by serum proteases 
(Nollmann et al., 2013) and other enzymes, especially 
via β-elimination reaction (Figure 9). An important 
requirement is that the linker does not leave any residue on 
the protein after cleavage of the bond. Pharmacodynamic 
response must also be controlled and optimized (Pasut, 
Veronese, 2012; Gong, Leroux, Gauthier, 2015).
Non-covalent PEGylation, in turn, is based in 
hydrophobic interactions (Pasut, Veronese, 2012), 
coordination complex formation (Mero et al., 2011), 
protein-polyelectrolyte and protein-block copolymers 
complexes (Kurinomaru, Shiraki, 2015). Research on this 
particular type of PEGylation has increased in recent years 
FIGURE 8 - Site-specific PEGylation of protein with transglutaminase (TGase) strategy, where GLN residue are PEGylated in the 
presence of TGase. 
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and promising results have been observed, but a more 
extensive study is still needed, especially to demonstrate 
significant improvement in pharmacokinetic properties 
(Pfister, Morbidelli, 2014).
One of the main disadvantages of this type of 
PEGylation refers to the release of the protein during 
purification steps or during storage, which is inherent 
to non-covalent conjugates. To avoid cleavage during 
storage, additional techniques such as lyophilization are 
required. This can be a challenge due to the difficulty of 
preserving PEGylated protein structure/activity during the 
freezing step (Pasut, Veronese, 2012; Kolate et al., 2014).
CURRENT ADVANCES IN THE PURIFICATION 
OF PEGYLATED PROTEINS
PEGylat ion react ions commonly resul t  in 
heterogeneous mixtures of unreacted protein, PEGylated 
conjugates and undesired PEGamers (proteins with 
varying number of attached PEG molecules) (Yoshimoto, 
Yamamoto, 2012; Moosmann, Müller, Böttinger, 2014). 
Furthermore, PEGylated conjugates dissimilar among 
themselves may be formed, with different number of 
grafted chains, length and attaching sites. Therefore, 
efficient downstream strategies are needed to purify these 
complex mixtures for commercial approval (Yoshimoto, 
Yamamoto, 2012). Purification of PEGylated proteins 
implies three main challenges: (i) isolation and recycling 
of the unreacted protein from the PEGylated proteins, 
(ii) isolation of each PEGylated protein form from the 
reaction media (e.g. PEG derivate, undesired PEGamers 
and other reagents such as hydroxylamine), and (iii) 
fractionation of PEGylated conjugates based on the degree 
of PEGylation. This multifaceted challenge is not easy to 
overcome since PEG-protein conjugates are structurally 
similar to the originator protein (González-Valdez, 
Rito-Palomares, Benavides, 2012). A combination of 
chromatographic (Moosmann, Müller, Böttinger, 2014) 
and/or non-chromatographic (Mayolo-Deloisa et al., 
2011) techniques is usually designed for each PEGylation 
process, exploiting the physicochemical properties of the 
molecules present in the PEGylation reaction mixture. In 
the last years, chromatographic fractionation platforms 
have been commonly used in downstream processes 
of PEGylated proteins (Fee, 2003; Moosmann et al., 
2010; 2014; Müller et al., 2010; Mayolo-Deloisa et al., 
2012), as shown in Figure 10. Non-chromatographic 
techniques have been suggested alternatively in the 
recent years, since they can exhibit advantages such as 
high versatility, ease of scale-up and low overall cost and 
time of processing (Cramer, Holstein, 2011). However, 
these are not fully characterized for the fractionation and 
analysis of PEGylated conjugates (Mayolo-Deloisa et al., 
2011). Currently, efforts are being made to characterize 
and optimize those purification platforms for a larger 
spectrum of PEGylated proteins (Mayolo-Deloisa et al., 
2011; Galindo-López, Rito-Palomares, 2013).
Chromatographic fractionation platforms
As mentioned above, most part of the purification 
processes for PEGylated proteins are based on 
chromatographic techniques, especially size exclusion 
chromatography (SEC) (Maiser et al., 2015) and ion 
exchange chromatography (IEX) (Zhao et al., 2012). 
SEC is a chromatographic method in which molecules 
in solution are separated by molecular weight (MW). 
It is well recognized that SEC can be used to separate 
PEGylated species from unreacted protein and other 
components, but the effectiveness will greatly depend upon 
FIGURE 9 - Schematic representation of a reversible PEGylation with Glyco-PEG.
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the molecular size of the species involved (Silva Freitas, 
Abrahao-Neto, 2010). For instance, the conjugation of 
a single PEG polymer with a protein with the same MW 
more than double the protein molecular radius, due to the 
steric elongation of PEG chains (Fee, Van Alstine, 2011). 
Therefore, native and mono-PEGylated proteins should 
be readily separable by SEC (Fee, Van Alstine, 2004). 
Nonetheless, the resolution among chromatographic 
peaks lowers as PEGylation extent increases, due to the 
presence of more PEGylated conjugates (Fahrländer et 
al., 2015; Maiser et al., 2015). SEC is not able to purify 
the positional isomers of PEGylated conjugates, due 
to the minimal radius differences among these protein 
species (Fee, Van Alstine, 2011). Proteins of different 
degrees of PEGylation may be separated by IEX since 
for each PEG molecule attached to an amino group, for 
example, a PEGylated protein has one less positive charge 
and this chromatographic technique separates proteins 
based on net surface charge (Fee, Van Alstine, 2011). 
By choosing the optimal ion exchanger and separation 
conditions, high resolution can be obtained. The best 
protocol must be achieved case-by-case depending on 
the specific protein and type of PEGylation (Fee, Van 
Alstine, 2011). In the recent years, IEX has been the 
most used downstream technique for the separation 
of PEGylated conjugates (Figure 10) (Abe et al., 2010; 
Moosmann et al., 2012; Zhao et al., 2012; Morgenstern 
et al., 2017). The major challenge of IEX refers to the 
fact that PEG chains sterically interfere in the interaction 
of the protein charged residues and the ionic exchange 
support, producing a masking effect of the charges (Fee, 
Van Alstine, 2011). 
Hydrophobic interaction chromatography (HIC) is 
also used to fractionate PEGylated proteins (Müller et al., 
2010; Mayolo-Deloisa et al., 2012; Moosmann, Müller, 
Böttinger, 2014), although not so extensively as IEX and 
SEC. HIC takes advantage of the hydrophobicity changes 
through PEGylation process, separating PEGylated 
conjugates based on the relative hydrophobicity/
hydrophilicity (Fee, Van Alstine, 2011). However, HIC 
has low capacity and poor resolution between adjacent 
peaks. To date, it is not possible to conclude which 
type of chromatographic technique is the best option to 
fractionate PEGylated conjugates. Furthermore, there 
is no generalized chromatographic protocols to purify 
PEGylated proteins, separation strategies must be 
developed on a case-by-case basis (Fee, Van Alstine, 2011; 
Mayolo-Deloisa et al., 2011). 
Non-chromatographic fractionation platforms
The non-chromatographic fractionation platforms 
applied in the purification of PEGylated proteins are: 
capillary electrophoresis (CE), membrane separation 
techniques (ultrafiltration, diafiltration and dialysis) and 
aqueous biphasic systems (ABS) (Mayolo-Deloisa et al., 
2011). Membrane separation processes are the simplest 
among all non-chromatographic techniques currently used 
and are based on the molecular weight and hydrodynamic 
radius of the proteins. PEGylated species can be efficiently 
fractionated and recovered using ultrafiltration and 
diafiltration (Cheang, Zydney, 2003; Ruanjaikaen, Zydney, 
2011). However, ultrafiltration methods may generate high 
product losses, particularly when using membranes with 
pores considerably smaller than the hydrodynamic radius 
of the PEGylated protein (Kwon, Molek, Zydney, 2008). 
Even though membrane separation techniques are not 
able to separate conjugates according to their positional 
isomerism, they present certain advantages, such as costs, 
over SEC and IEX. Capillary electrophoresis (CE) proved 
to be a powerful tool for the high-resolution separation 
of different PEGylated products; it has been used in 
the analysis and small-scale purification of PEGylated 
proteins (Li et al., 2001; Na et al., 2008; Lee, Na, 2010). 
The major advantages of this technique are its automation 
capability, low sample consumption and short-time 
FIGURE 10 - Distribution of the publications/papers reported in 
the last 7 years (> 2010) dealing with chromatographic and non-
chromatographic techniques for the separation of PEGylated 
proteins in Web of Science and Pubmed databases. SEC – size 
exclusion chromatography, IEX – ion exchange chromatography, 
HIC – hydrophobic interaction chromatography.
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process (Caslavska, Thormann, 2004). On the other hand, 
CE lacks in the industrial process due to technique scale-
up incapability. 
To overcome the main drawbacks of  non-
chromatographic downstream processes, the use of 
microfluidic devices is emerging as a promising strategy 
for high-throughput monitoring of protein PEGylation 
purification. The design of these novel devices for rapid 
separation, concentration, and recovery of PEGylated 
proteins in a one-step operation is a current trend for non-
chromatographic downstream processes (Yoshimoto, 
Yamamoto, 2012; Mata-Gómez et al., 2016).
Aqueous biphasic systems offer a great alternative 
of an efficient downstream processing platform for 
PEGylated proteins due to their versatility, ease of scale 
up and low costs (Santos et al., 2017). Several works 
addressed the application of ABS as purification tools to 
be used in the separation of PEGylated proteins (Delgado 
et al., 1994; González-Valdez et al., 2011; González-
Valdez, Rito-Palomares, Benavides, 2013; Santos et al., 
2017). Delgado et al. (1994) used PEG/dextran ABS to 
characterize the degree of PEGylation (n) in mixtures 
of PEG-protein conjugates of bovine serum albumin 
and granulocyte-macrophage colony stimulating factor. 
These authors determined the relationship between the 
increase in partition coefficient (K) of the PEGylated 
conjugate with the degree of PEGylation of the protein 
species present in the resulting mixtures. González-
Valdez et al. (2011) studied PEG/salt-based ABS for 
the separation of native RNase A and lactoalbumin 
and their respective PEGylated conjugates. The results 
indicated the potential of ABS for the fractionation 
of PEGylated proteins from the respective unreacted 
proteins. However the sub-fractionation of PEGylated 
proteins from themselves (depending on the degree of 
PEGylation) was not achieved. Extended applications 
of ABS were achieved with the combination of this 
technique with continuous scale-up platforms, such as 
the counter current distribution ABS (CCD-ABS). The 
application of CCD-ABS was already performed for 
the fractionation of PEGylated forms of lysozyme and 
RNase (Sookkumnerd, Hsu, 2000; Galindo-López, Rito-
Palomares, Benavides, 2013). 
Despite the advances reported, other types of ABS, 
such as PEG/polyacrylate (with or without electrolytes 
present), PEG/ionic liquids, copolymer/salt are worth 
investigating for the fractionation of PEGylated conjugates 
with different degrees of PEGylation. In situ product 
recovery through ABS in continuous regime and the 
application of other approaches regarding continuous 
flow purification, namely the centrifugal partition 
chromatography (CPC), should also be focused in the near 
future (Mayolo-Deloisa et al., 2011). 
CHARACTERIZATION OF PEGYLATED PRO-
TEINS 
To obtain a valid PEGylation reaction and to 
characterize/quantify PEGylated conjugates, several 
analytical techniques must be applied. These techniques 
must be adapted to the specific polymer–protein conjugates 
and be able to access their (i) structural arrangement, (ii) 
bioactivity potential and (iii) stability. 
In terms of structural analysis of the PEGylated 
conjugates, it is important to determine the molecular 
mass, the number of bound polymer chains, the specific 
sites of PEG attachment and the secondary and tertiary 
structure (González-Valdez, Rito-Palomares, Benavides, 
2012). Together with UV–visible spectrophotometry and 
electrophoresis, size exclusion chromatography (SEC), 
mass spectrometry (MS), fourier-transform infrared 
spectroscopy (FTIR), circular dichroism (CD) and 
dynamic light scattering (DLS) are the major techniques 
used to characterize the molecular mass and structure 
of PEGylated proteins and are of great prominence in 
biobetters manufacturing and quality control. 
Generally, the first step for structural characterization 
is polyacrylamide gel electrophoresis (PAGE), and/or 
western blotting to confirm the identity of the PEGylated 
protein (Zhou, He, Wang, 2016). However, PEG may 
change the electrophoretic mobility, which complicates 
size characterization, being this technique of low precision 
(González-Valdez, Rito-Palomares, Benavides, 2012). 
The mass of PEGylated species is commonly evaluated 
by MS, which is also capable of identifying the specific 
sites and number of attached polymer chains in the primary 
amino acid sequence (Domon, Aebersold, 2006). MALDI-
TOF MS has been employed the technique of choice to 
characterize average molecular weight and degree of 
PEGylation (Chowdhury, Doleman, Johnston, 1995; 
Bullock, Chowdhury, Johnston, 1996; Wang et al., 2002; 
Na, Youn, Lee, 2004; Yun et al., 2005). Irrespectively of 
the size and type of PEG used (mono and heterofunctional, 
linear or branched), MALDI provides first-rate information 
on molecular weight, total amount and distribution of PEG 
on protein, besides site specific information on PEGylation 
coupling site (Cindrić et al., 2007). On the other hand, 
electrospray ionization MS (ESI-MS) have been gaining 
attention in the past decade for the analysis of PEGylated 
proteins (Cindrić et al., 2007; Forstenlehner et al., 2014). 
Compared to MALDI, ESI-MS has some advantages such 
as automated workflow and reduced sample preparation 
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time (Gioacchini et al., 1997). Yet, the overlapping protein 
charge pattern and the polydispersity of the PEGylation 
derivatives make it difficult to understand and analyse the 
ESI-MS spectrum. Some additional techniques have been 
alternatively employed, namely tryptic digestion (Wu et 
al., 2011) and isotopically labelled internal standards of 
PEGylated proteins (Watson et al., 1994). SEC can also 
bee applied to infer the size of PEGylated proteins (Fee, 
Van Alstine, 2004). However, some studies suggest that 
the determination of PEGylated proteins mass through this 
technique is not as adequate as using MS (Fee, Van Alstine, 
2004; González-Valdez, Rito-Palomares, Benavides, 
2012). The apparent PEG interaction with the material 
of SEC columns could lead to anomalously slow elution 
times of PEGylated proteins and, thus, incorrect molecular 
weight determinations (Fee, Van Alstine, 2004).
 After the confirmation of the PEGylated protein 
mass and polydispersity, the effect of PEGylation in the 
secondary and tertiary structure of the protein should be 
evaluated and CD spectroscopy is a powerful technique 
for this end. Through far UV CD (data collected from ~190 
to 250 nm) and near UV CD (data collected from 250 to 
300 nm) it is possible to infer about the protein secondary 
and tertiary structure, respectively. Additionally, CD can 
also be used to study protein stability as a function of 
temperature or denaturing conditions. FTIR spectroscopy 
can be alternatively used to evaluate the effect of PEG on 
the protein secondary structure, however it is less sensitive 
than CD (Rajan et al., 2006). 
The hydrodynamic diameter of PEGylated proteins 
is also of importance to identify different PEG-protein 
conjugates and it can be estimated based on DLS 
measurements (Gokarn, McLean, Laue, 2012). DLS is 
the most conventional method for determination and 
characterization of nanoparticles. In PEGylation, usually 
the hydrodynamic diameter of a conjugate is increased by 
the addition of PEGs in the protein (at least up to three PEG 
molecules) (Gokarn, McLean, Laue, 2012). 
The determination of a PEGylated protein 
biological activity is one of the most important steps for 
characterization (Fontana et al., 2008; Jevševar, Kunstelj, 
Porekar, 2010; González-Valdez, Rito-Palomares, 
Benavides, 2012). For enzymes, in particular, kinetic 
parameters must be determined (e.g. Km, kcat and vmax). 
Additionally, in vivo bioactivity must be confirmed for 
PEGylated proteins. A decrease in PEGylated protein 
activity can be observed depending on the reaction site, 
since the covalent attachment of PEG impairs restrictions 
in molecular conformation (Hsieh, Lin, 2015; Morgenstern 
et al., 2017). Other methods currently used to quantify 
biological activity involve bioassays, immunoassays, 
and radioassays. Finally, stability assays are crucial to 
identify the most stable PEGylated isoform as a promising 
biobetter. Protein stability assessment should be performed 
considering the thermostability (Santiago-Rodríguez et 
al., 2011; Hsieh, Lin, 2015), long term stability (Santiago-
Rodríguez et al., 2011), pH stability (Tian et al., 2013) and 
proteolytic digestion assays (Kurinomaru, Shiraki, 2015). 
Overall, a protein PEGylation process to develop 
a biobetter can be defined as a multi-step approach 
(Figure 11), in which the complete analysis of the 
technological and economical benefits of each step 
should be attained to make it viable to pharmaceutical and 
biotechnological industries.
CONCLUSIONS
PEGylation is an attractive and prospective tool to 
improve drug properties, especially protein drugs. Despite 
all molecular biology tools available today, it is still one 
FIGURE 11 - Flow diagram of the PEGylation bioprocess operation from reaction design to purification and characterization, 
ending up with the final application of the chemically modified protein drugs as an effective biobetter. 
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of the main strategies for biobetters development. The 
overall process must be considered to develop a PEGylated 
protein, from the chemical reaction to the proper 
PEGylated protein purification, what can be considered the 
PEGylation downstream step. The reaction step involves 
proper selection of the PEGylation reagents and chemistry, 
what is crucial for the final product characteristics and its 
application. There is no better chemistry, it will depend 
on the protein drug characteristics, such as if it need to 
be detached from PEG to present activity and for how 
long it should circulate in the body. After the reaction, 
downstream steps will include the fractionation and 
purification of PEG-protein conjugates, followed by the 
complete structural and activity characterization of the 
resulting species. High degree of purity is needed for 
protein drugs and for this reason it is hard to imagine 
industrial purification processes without including the 
chromatographic steps already in use. Nonetheless, the 
complete analysis of the technological and economic 
benefits of PEGylation could support biopharmaceutical 
industries in seeking for more efficient strategies to 
develop biobetters. 
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